SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia receiving fludarabine regimens as initial therapy. Blood. 1998; 92: 11651171.
  • 2
    Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000; 343: 17501757.
  • 3
    Robak T. The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia—lessons learned from prospective randomized trials. Leuk Lymphoma. 2002; 43: 537548.
  • 4
    Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated Stage B and C chronic lymphocytic leukemia patients. Blood. 2001; 98: 23192325.
  • 5
    Keating MJ, O'Brien S, Robertson LE, et al. New initiatives with fludarabine monophosphate in hematologic malignancies. Semin Oncol. 1993; 20(5 Suppl 7 ): 1320.
  • 6
    Mauro FR, Foa R, Meloni G, et al. Fludarabine, ara-C, novantrone and dexamethasone in previously treated chronic lymphocytic leukemia patients. Haematologica. 2002; 87: 926933.
  • 7
    Hallek M, Schmitt B, Wilhelm M, et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia: results of a Phase II study of the German CLL Study Group. Br J Haematol. 2001; 114: 342348.
  • 8
    Schmitt B, Wendtner CM, Bergmann M, et al. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Clin Lymphoma. 2002; 3: 2635.
  • 9
    O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001; 19: 14141420.
  • 10
    Giles FJ, O'Brien SM, Santini V, et al. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a Phase II study. Leuk Lymphoma. 1999; 36: 5765.
  • 11
    Morrison VA, Rai KR, Peterson BL, et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol. 2001; 19: 36113621.
  • 12
    Tsimberidou AM, Kantarjian HM, Cortes J, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003; 97: 17111720.
  • 13
    O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 1993; 82: 16951700.
  • 14
    McLaughlin P, Hagemeister FB, Swan F Jr., et al. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol. 1994; 12: 575579.
  • 15
    McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996; 14: 12621268.
  • 16
    Morabito F, Callea I, Console G, et al. The in vitro cytotoxic effect of mitoxantrone in combination with fludarabine or pentostatin in B-cell chronic lymphocytic leukemia. Haematologica. 1997; 82: 560565.
  • 17
    Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood. 1999; 94: 28362843.
  • 18
    Bellosillo B, Colomer D, Pons G, Gil J. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998; 100: 142146.
  • 19
    Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 49904997.
  • 20
    National Cancer Institute Cancer Therapy Evaluation Program. Revised common toxicity criteria. Version 2.0 [monograph online]. Available from URL: http://ctep.info.nih.gov/reporting/CTC-3.html[accessed March 2003].
  • 21
    Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 22
    Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 1996; 347: 14321438.
  • 23
    Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia. 2002; 16: 10151027.
  • 24
    Marotta G, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica. 2000; 85: 12681270.
  • 25
    Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000; 96: 7175.
  • 26
    Zaja F, Rogato A, Russo D, Marin L, Silvestri F, Baccarani M. Combined therapy with fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas. Eur J Haematol. 1997; 59: 327328.
  • 27
    Frewin R, Turner D, Tighe M, Davies S, Rule S, Johnson S. Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br J Haematol. 1999; 104: 612613.
  • 28
    Keating MJ, Manshouri T, O'Brien S, et al. A high proportion of true complete remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocytic leukemia [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 569.
  • 29
    Byrd JC, Peterson BL, Morrison VA, et al. Randomized Phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003; 101: 614.
  • 30
    Keating MJ, Kantarjian H, O'Brien S, et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol. 1991; 9: 4449.
  • 31
    Flinn IW, Jemiai Y, Bennett JM, et al. Fludarabine and cyclophosphamide achieves high complete response rate in patients with previously untreated chronic lymphocytic leukemia. ECOG 1997 [abstract]. Blood. 2001; 98: 632a.
  • 32
    Cazin B, Maloum K, Divine M, et al. Oral fludarabine and cyclophosphamide in previously untreated CLL: preliminary data on 59 patients [abstract]. Blood. 2001; 98: 772a.
  • 33
    Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood. 1995; 86: 24632474.
  • 34
    Fenchel K, Bergmann L, Wijermans P, et al. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. Leuk Lymphoma. 1995; 18: 485492.
  • 35
    Hiddemann W, Rottmann R, Wormann B, et al. Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical Phase-II study. Ann Hematol. 1991; 63: 14.
  • 36
    Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989; 74: 1925.
  • 37
    Rummel MJ, Kafer G, Pfreundschuh M, et al. Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter Phase II study. Ann Oncol. 1999; 10: 183188.
  • 38
    Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol. 2002; 119: 976984.
  • 39
    Emmanouilides C, Rosen P, Rasti S, Territo M, Kunkel L. Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a Phase II trial. Hematol Oncol. 1998; 16: 107116.
  • 40
    Velasquez WS, Lew D, Grogan TM, et al. Combination of fludarabine and mitoxantrone in untreated Stages III and IV low-grade lymphoma: S9501. J Clin Oncol. 2003; 21: 19962003.
  • 41
    Zinzani PL, Magagnoli M, Bendandi M, et al. Efficacy of fludarabine and mitoxantrone combination regimen in untreated indolent non-Hodgkin's lymphomas. Ann Oncol. 2000; 11: 363365.
  • 42
    Gregory SA, Vose J, Modiano M, et al. Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicin or mitoxantrone-containing regimen. Leuk Lymphoma. 2001; 40: 315324.
  • 43
    Seymour JF, Grigg AP, Szer J, Fox RM. Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Ann Oncol. 2001; 12: 14551460.
  • 44
    Tsimberidou AM, McLaughlin P, Younes A, et al. Fludarabine, mitoxantrone, dexamethasone compared with an alternating triple therapy regimen in patients with Stage IV indolent lymphoma. Blood. 2002; 100: 43514357.
  • 45
    Crawley CR, Foran JM, Gupta RK, et al. A Phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone in patients with follicular lymphoma. Ann Oncol. 2000; 11: 861865.
  • 46
    Davis JW, Weiss NS, Armstrong BK. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst. 1987; 78: 9194.
  • 47
    Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998; 338: 15061514.
  • 48
    Molica S, Alberti A. Second neoplasms in chronic lymphocytic leukemia: analysis of incidence as a function of the length of follow-up. Haematologica. 1989; 74: 481485.
  • 49
    Travis LB, Curtis RE, Hankey BF, Fraumeni JF Jr. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst. 1992; 84: 14221427.
  • 50
    Catovsky D, Fooks J, Richards S. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br J Haematol. 1989; 72: 141149.
  • 51
    Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol. 1999; 17: 24542460.